Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility are currrently unavailable.

Stephen Harvey Zinner, M.D.

Concepts

This page shows the publications Stephen Zinner has written about Anti-Bacterial Agents.
Connection Strength

3.606
  1. Profile of a Novel Anionic Fluoroquinolone-Delafloxacin. Clin Infect Dis. 2019 04 08; 68(Suppl 3):S213-S222.
    View in: PubMed
    Score: 0.216
  2. Predicting antibiotic combination effects on the selection of resistant Staphylococcus aureus: In vitro model studies with linezolid and gentamicin. Int J Antimicrob Agents. 2018 Dec; 52(6):854-860.
    View in: PubMed
    Score: 0.207
  3. Testing the mutant selection window hypothesis with Staphylococcus aureus exposed to linezolid in an in vitro dynamic model. J Antimicrob Chemother. 2017 Nov 01; 72(11):3100-3107.
    View in: PubMed
    Score: 0.195
  4. Burden of antimicrobial resistance in an era of decreasing susceptibility. Expert Rev Anti Infect Ther. 2017 07; 15(7):663-676.
    View in: PubMed
    Score: 0.190
  5. Pharmacokinetically-based prediction of the effects of antibiotic combinations on resistant Staphylococcus aureus mutants: in vitro model studies with linezolid and rifampicin. J Chemother. 2017 Aug; 29(4):220-226.
    View in: PubMed
    Score: 0.182
  6. Bacterial antibiotic resistance studies using in vitro dynamic models: Population analysis vs. susceptibility testing as endpoints of mutant enrichment. Int J Antimicrob Agents. 2015 Sep; 46(3):313-8.
    View in: PubMed
    Score: 0.166
  7. Antibiotic Development and the Evolving Role of Pharmacodynamics - As Good as It Gets? EBioMedicine. 2015 Jul; 2(7):615-6.
    View in: PubMed
    Score: 0.165
  8. Predicting bacterial resistance using the time inside the mutant selection window: possibilities and limitations. Int J Antimicrob Agents. 2014 Oct; 44(4):301-5.
    View in: PubMed
    Score: 0.156
  9. Bacterial resistance studies using in vitro dynamic models: the predictive power of the mutant prevention and minimum inhibitory antibiotic concentrations. Antimicrob Agents Chemother. 2013 Oct; 57(10):4956-62.
    View in: PubMed
    Score: 0.145
  10. Paul Ehrlich, a prescient pioneer in the field of antimicrobial chemotherapy: what did he foresee a century ago? Expert Rev Anti Infect Ther. 2013 Feb; 11(2):113-5.
    View in: PubMed
    Score: 0.140
  11. Concentration-resistance relationships with Pseudomonas aeruginosa exposed to doripenem and ciprofloxacin in an in vitro model. J Antimicrob Chemother. 2013 Apr; 68(4):881-7.
    View in: PubMed
    Score: 0.139
  12. Comparative pharmacodynamics and antimutant potentials of doripenem and imipenem with ciprofloxacin-resistant Pseudomonas aeruginosa in an in vitro model. Antimicrob Agents Chemother. 2012 Mar; 56(3):1223-8.
    View in: PubMed
    Score: 0.130
  13. Enrichment of resistant Staphylococcus aureus at ciprofloxacin concentrations simulated within the mutant selection window: bolus versus continuous infusion. Int J Antimicrob Agents. 2008 Dec; 32(6):488-93.
    View in: PubMed
    Score: 0.104
  14. Antibiotic use: present and future. New Microbiol. 2007 Jul; 30(3):321-5.
    View in: PubMed
    Score: 0.095
  15. The search for new antimicrobials: why we need new options. Expert Rev Anti Infect Ther. 2005 Dec; 3(6):907-13.
    View in: PubMed
    Score: 0.085
  16. Overview of antibiotic use and resistance: setting the stage for tigecycline. Clin Infect Dis. 2005 Sep 01; 41 Suppl 5:S289-92.
    View in: PubMed
    Score: 0.084
  17. Comparative pharmacodynamics of the new fluoroquinolone ABT492 and levofloxacin with Streptococcus pneumoniae in an in vitro dynamic model. Int J Antimicrob Agents. 2005 May; 25(5):409-13.
    View in: PubMed
    Score: 0.082
  18. Fluoroquinolone prophylaxis in patients with neutropenia. Clin Infect Dis. 2005 Apr 15; 40(8):1094-5.
    View in: PubMed
    Score: 0.081
  19. Anti-mutant efficacy of antibiotic combinations: in vitro model studies with linezolid and daptomycin. J Antimicrob Chemother. 2021 06 18; 76(7):1832-1839.
    View in: PubMed
    Score: 0.063
  20. Predicting the antistaphylococcal effects of daptomycin-rifampicin combinations in an in vitro dynamic model. J Antibiot (Tokyo). 2020 02; 73(2):101-107.
    View in: PubMed
    Score: 0.056
  21. Resistance studies with Streptococcus pneumoniae using an in vitro dynamic model: amoxicillin versus azithromycin at clinical exposures. J Chemother. 2019 Sep; 31(5):252-260.
    View in: PubMed
    Score: 0.055
  22. Time inside the mutant selection window as a predictor of staphylococcal resistance to linezolid. J Antibiot (Tokyo). 2018 05; 71(5):514-521.
    View in: PubMed
    Score: 0.050
  23. Predicting effects of antibiotic combinations using MICs determined at pharmacokinetically derived concentration ratios: in vitro model studies with linezolid- and rifampicin-exposed Staphylococcus aureus. J Chemother. 2017 Oct; 29(5):267-273.
    View in: PubMed
    Score: 0.046
  24. Searching for the Optimal Predictor of Ciprofloxacin Resistance in Klebsiella pneumoniae by Using In Vitro Dynamic Models. Antimicrob Agents Chemother. 2015 Dec 07; 60(3):1208-15.
    View in: PubMed
    Score: 0.043
  25. Predictors of bacterial resistance using in vitro dynamic models: area under the concentration-time curve related to either the minimum inhibitory or mutant prevention antibiotic concentration. J Antimicrob Chemother. 2016 Mar; 71(3):678-84.
    View in: PubMed
    Score: 0.043
  26. In vitro resistance studies with bacteria that exhibit low mutation frequencies: prediction of "antimutant" linezolid concentrations using a mixed inoculum containing both susceptible and resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2015 Feb; 59(2):1014-9.
    View in: PubMed
    Score: 0.040
  27. The antistaphylococcal pharmacodynamics of linezolid alone and in combination with doxycycline in an in vitro dynamic model. J Chemother. 2011 Jun; 23(3):140-4.
    View in: PubMed
    Score: 0.031
  28. Enhancement of leucocyte killing of resistant bacteria selected during exposure to aminoglycosides or quinolones. J Antimicrob Chemother. 1990 Jun; 25(6):941-8.
    View in: PubMed
    Score: 0.029
  29. The impact of duration of antibiotic exposure on bacterial resistance predictions using in vitro dynamic models. J Antimicrob Chemother. 2009 Oct; 64(4):815-20.
    View in: PubMed
    Score: 0.028
  30. Telavancin and vancomycin pharmacodynamics with Staphylococcus aureus in an in vitro dynamic model. J Antimicrob Chemother. 2008 Nov; 62(5):1065-9.
    View in: PubMed
    Score: 0.026
  31. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrob Agents Chemother. 1987 Jul; 31(7):1054-60.
    View in: PubMed
    Score: 0.024
  32. Concentration-response relationships as a basis for choice of the optimal endpoints of the antimicrobial effect: daptomycin and vancomycin pharmacodynamics with staphylococci in an in vitro dynamic model. Int J Antimicrob Agents. 2007 Feb; 29(2):165-9.
    View in: PubMed
    Score: 0.023
  33. In vitro models for the study of antibiotic activities. Prog Drug Res. 1987; 31:349-81.
    View in: PubMed
    Score: 0.023
  34. Testing the mutant selection window hypothesis with Staphylococcus aureus exposed to daptomycin and vancomycin in an in vitro dynamic model. J Antimicrob Chemother. 2006 Dec; 58(6):1185-92.
    View in: PubMed
    Score: 0.023
  35. In vitro antimicrobial activity of moxifloxacin against bacterial strains isolated from blood of neutropenic cancer patients. Eur J Clin Microbiol Infect Dis. 2006 Aug; 25(8):537-40.
    View in: PubMed
    Score: 0.022
  36. In vitro models for the study of combination antibiotic therapy in neutropenic patients. Am J Med. 1986 Jun 30; 80(6B):156-60.
    View in: PubMed
    Score: 0.022
  37. In vitro models in the study of antibiotic therapy of infections in neutropenic patients. Am J Med. 1986 May 30; 80(5C):40-4.
    View in: PubMed
    Score: 0.022
  38. Laboratory support for choosing and monitoring antimicrobial therapy in severely ill patients. Am J Med. 1986 May 30; 80(5C):59-63.
    View in: PubMed
    Score: 0.022
  39. Influence of medium and method on the in vitro susceptibility of Pseudomonas aeruginosa and other bacteria to ciprofloxacin and enoxacin. Antimicrob Agents Chemother. 1986 May; 29(5):927-9.
    View in: PubMed
    Score: 0.022
  40. In-vitro studies of antibiotic combinations with special emphasis on the evaluation of newly developed methods. J Antimicrob Chemother. 1986 Mar; 17 Suppl A:1-5.
    View in: PubMed
    Score: 0.022
  41. Comparative pharmacodynamics of telithromycin and clarithromycin with Streptococcus pneumoniae and Staphylococcus aureus in an in vitro dynamic model: focus on clinically achievable antibiotic concentrations. Int J Antimicrob Agents. 2005 Sep; 26(3):197-204.
    View in: PubMed
    Score: 0.021
  42. Use of an in-vitro kinetic model to study antibiotic combinations. J Antimicrob Chemother. 1985 Jan; 15 Suppl A:221-6.
    View in: PubMed
    Score: 0.020
  43. Two compartment kinetic model with multiple artificial capillary units. J Antimicrob Chemother. 1985 Jan; 15 Suppl A:131-7.
    View in: PubMed
    Score: 0.020
  44. Comparison of tube dilution and microtitre methods for the detection of antibiotic tolerance in strains of Staphylococcus aureus. J Antimicrob Chemother. 1984 May; 13(5):417-21.
    View in: PubMed
    Score: 0.019
  45. Prevention of the selection of resistant Staphylococcus aureus by moxifloxacin plus doxycycline in an in vitro dynamic model: an additive effect of the combination. Int J Antimicrob Agents. 2004 May; 23(5):451-6.
    View in: PubMed
    Score: 0.019
  46. In-vitro activity of aztreonam in combination with four other antibiotics against gram-negative bacilli and Staphylococcus aureus. J Antimicrob Chemother. 1984 Apr; 13(4):398-9.
    View in: PubMed
    Score: 0.019
  47. Prophylaxis of bacterial infections with oral antibiotics in neutropenic patients. Lessons from the last two EORTC trials and prospects for the future. Schweiz Med Wochenschr Suppl. 1983; 14:7-14.
    View in: PubMed
    Score: 0.017
  48. Synergism of trimethoprim combined with aminoglycosides in vitro and in serum of volunteers. Eur J Clin Microbiol. 1982 Jun; 1(3):144-8.
    View in: PubMed
    Score: 0.017
  49. Synergistic combinations of antibiotics in gram-negative bacillary infections. Rev Infect Dis. 1982 Mar-Apr; 4(2):294-301.
    View in: PubMed
    Score: 0.016
  50. Comparative pharmacodynamics of azithromycin and roxithromycin with S. pyogenes and S. pneumoniae in a model that simulates in vitro pharmacokinetics in human tonsils. J Antimicrob Chemother. 2002 Jan; 49(1):113-9.
    View in: PubMed
    Score: 0.016
  51. Simulated in vitro quinolone pharmacodynamics at clinically achievable AUC/MIC ratios: advantage of I E over other integral parameters. Chemotherapy. 2002; 48(6):275-9.
    View in: PubMed
    Score: 0.016
  52. Antistaphylococcal activity of rifampin with other antibiotics. J Infect Dis. 1981 Oct; 144(4):365-71.
    View in: PubMed
    Score: 0.016
  53. In vitro and in vivo studies of three antibiotic combinations against gram-negative bacteria and Staphylococcus aureus. Antimicrob Agents Chemother. 1981 Oct; 20(4):463-9.
    View in: PubMed
    Score: 0.016
  54. Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on gram-positive and resistant bacteria. Clin Infect Dis. 1999 Sep; 29(3):490-4.
    View in: PubMed
    Score: 0.014
  55. Concentration-dependent enrichment of resistant Enterococcus faecium exposed to linezolid in an in vitro dynamic model. J Chemother. 2018 Oct - Dec; 30(6-8):364-370.
    View in: PubMed
    Score: 0.013
  56. Approach to fever in the neutropenic host. Cancer Treat Res. 1998; 96:77-104.
    View in: PubMed
    Score: 0.012
  57. Empiric antimicrobial therapy for febrile granulocytopenic cancer patients: lessons from four EORTC trials. Eur J Cancer Clin Oncol. 1988; 24 Suppl 1:S35-45.
    View in: PubMed
    Score: 0.006
  58. Vaginal colonization with mycoplasma hominis and ureaplasma urealyticum. Sex Transm Dis. 1986 Apr-Jun; 13(2):67-70.
    View in: PubMed
    Score: 0.005
  59. Review of amikacin usage in the EORTC trials. Am J Med. 1985 Jul 15; 79(1A):17-20.
    View in: PubMed
    Score: 0.005
  60. Bacterial pathogens of increasing significance in hospital-acquired infections. Rev Infect Dis. 1985 Jul-Aug; 7 Suppl 3:S371-9.
    View in: PubMed
    Score: 0.005
  61. Serum bactericidal activity of moxalactam and cefotaxime with and without tobramycin against Pseudomonas aeruginosa and Staphylococcus aureus. Antimicrob Agents Chemother. 1981 Oct; 20(4):539-41.
    View in: PubMed
    Score: 0.004
  62. Effect of mixing on rifampin bactericidal activity against staphylococci. Antimicrob Agents Chemother. 1981 Aug; 20(2):267-9.
    View in: PubMed
    Score: 0.004
  63. Three antibiotic regimens in the treatment of infection in febrile granulocytopenic patients with cancer. The EORTC international antimicrobial therapy project group. J Infect Dis. 1978 Jan; 137(1):14-29.
    View in: PubMed
    Score: 0.003
  64. Isolation of Eikenella corrodens in a general hospital. Appl Microbiol. 1973 May; 25(5):705-8.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.